Singapore markets close in 3 hours 59 minutes

Arcutis Biotherapeutics, Inc. (ARQT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.92+0.44 (+4.64%)
At close: 04:00PM EDT
10.20 +0.28 (+2.82%)
After hours: 06:29PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.48
Open9.52
Bid9.91 x 600
Ask9.94 x 600
Day's range9.52 - 10.77
52-week range1.76 - 13.17
Volume4,507,117
Avg. volume3,723,293
Market cap1.148B
Beta (5Y monthly)1.18
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

    First quarter net product revenues for ZORYVE® franchise of $21.6M, with $15M for ZORYVE (roflumilast) cream 0.3%, and $6.5M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 675% vs. Q1 '23 and 59% vs. Q4 '23Continued gross-to-net (GTN) improvement with blended GTN across products now in the low 60 percent rangeSustained growth in demand for cream and remarkable uptake of foam launched in JanuaryJuly 7, 2024 Prescription Drug User Fee Act (PDUFA) action date for roflumilast cream, 0.

  • GlobeNewswire

    Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

    Eight of nine experts expressed feeling “extremely confident” about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on review of formulation dataCrodafos™ CES, used in ZORYVE foam, is suitable for a wide variety of skin and hair typesFindings from this formulation review underscore the suitability of ZORYVE foam for use on all affected areas of the body, and all hair types, in the management of seborrheic dermatitis W

  • GlobeNewswire

    Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 160,500 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 117,000 shares of Arcutis’ common stock to 13 newly hired employees. These awards were approved by the Compensation Committee of Arcuti